New Survey: 84% of Respondents Would Participate in a Hospital-at-Home Program In Order To Get Home Sooner

June 13, 2024

More than 300 Hospital at Home (HaH) programs have been approved across the country, allowing thousands of patients to be monitored in the comfort of their homes after leaving the hospital.

Vivalink, a leading provider of digital healthcare solutions, is sharing results from a new survey of more than 1,000 U.S. consumers 40 years and older about their opinions surrounding participating in a HaH program.

Key findings from the survey include:

An overwhelming 84% of respondents are willing to participate in HaH monitoring in order to return home sooner versus staying at the hospital to be monitored.
77% of respondents indicated that they would trust their healthcare provider’s recommendation to utilize HaH monitoring.
Of those who have experienced HaH, 84% reported having a positive experience with the program.
49% of respondents who had participated in a HaH program found the remote patient monitoring (RPM) device easy to use. At the same time, of the 16% of respondents who were not likely to participate in HaH programs, difficulty with devices was cited as a top concern.

The survey also delved into demographic variations, uncovering insights based on age and location:

Older respondents (over 70) were less likely to have heard of HaH programs (42% vs. 77% of consumers in their 40s), or had participated in HaH programs (11% vs. 66%).
Urban participants were more likely to have participated in HaH programs (71% vs. 25% of rural respondents) but were less likely to prefer completely remote primary care compared to rural participants (19% vs. 36% of rural respondents).
Respondents with three or more hospitalizations in the last 12 months demonstrated a higher willingness to participate in HaH programs (95% vs. 62% of respondents with 2 or fewer hospitalizations) and expressed greater trust in providers’ recommendations for HaH monitoring (95% vs 78%).

The survey’s findings are particularly compelling as the waivers introduced by the Centers for Medicare and Medicaid Services (CMS) in response to the COVID-19 pandemic, which allowed inpatient-level hospital services to be conducted in patients’ homes, are set to expire at the end of this year, emphasizing the need for permanent adoption of flexible care models like HaH programs.

“Consumers are increasingly driving the trend towards receiving care in the comfort of their own homes. This shift, accelerated by the COVID pandemic, underscores the importance of providing flexible and convenient healthcare solutions that meet patients’ evolving needs,” said Jiang Li, CEO of Vivalink. “At Vivalink, we are committed to the development of advanced digital healthcare solutions in order to improve access and efficiency of the healthcare system for all.”

For more details and infographics, click here.

Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership

June 13, 2024

Jumpcode Genomics, a genome technology platform company focused on improving the understanding of human biology, and Takara Bio USA, Inc. (“Takara Bio USA”), a wholly-owned subsidiary of Takara Bio Inc., today announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.

Under the terms of the agreement Jumpcode Genomics and Takara Bio USA have each granted the other party a license to use their IP in exchange for an agreed royalty payment. The financial terms were not disclosed. The companies’ combined IP comprises multiple patents and patent applications worldwide, including U.S. Patent 11,708,606, held by Jumpcode, and U.S. Patent 10,150,985, held by Takara Bio USA.

The companies’ cutting-edge technologies, sold under the DepleteX® and CRISPRclean brands by Jumpcode and as ZapR technology by Takara Bio USA, remove unwanted sequences from biological samples to enable the discovery and detection of novel molecules. This enables researchers to significantly improve the sensitivity of their RNA-seq libraries and provides significant cost savings by reducing the need to sequence unwanted abundant sequences.

The technology can be used in multiple research and translational applications and has the potential to be utilized to rapidly detect unknown, previously undetectable pathogens, which is critically important, particularly in the event of a future pandemic.

Commenting on the partnership Mike Salter, President and CEO of Jumpcode, said:

“We are delighted to partner with Takara. Our combined technology is instrumental to scientists around the world enabling them to deliver groundbreaking research, and we are excited by its potential to transform the future of molecular biology. We look forward to working with Takara Bio USA as we focus on the global commercialisation of our products.”

Carol Lou, President & CEO of Takara Bio USA, said: “We are very pleased to be working with Jumpcode to bring together the innovative technology platforms and foundational IP of both companies. This agreement brings clarity for both Takara Bio USA’s and Jumpcode’s customers and partners and paves the way for both companies to combine their strengths to better enable genomics research.”

Nurse.com Unveils Next-Generation Talent Marketplace To Revolutionize Healthcare Hiring

June 13, 2024

Nurse.com: This is a community where more than 3 million nurses can connect with peers, apply for jobs, and earn continuing education, announced today the launch of its enhanced nurse talent marketplace with access to the largest and most relevant pool of nursing talent in the market. With access to 80% of the U.S. nursing workforce, Nurse.com’s proprietary skills-based matching technology ensures the right nurse with the right skills is delivered at the right time.

The enhanced talent marketplace facilitates seamless connections between healthcare organizations and qualified nurses by aligning their skills, experience, and training with open positions. With a deep understanding of nurses’ behavior and skills, Nurse.com utilizes next-generation technology, candidate data, and completed courses to deliver personalized job matches. This approach enables recruiters to find candidates who not only meet their organization’s needs but also fit its culture.

Felicia Sadler, MJ, BSN, RN, CPHQ, LSSBB, Vice President of Quality, Relias, Nurse.com advocate

“Our next-generation talent marketplace marks a significant milestone in healthcare talent acquisition. By leveraging insights from 18 million continuing education course completions, nurse behavior, and earned skills, we’re providing healthcare organizations with a cutting-edge solution to identify top nursing talent. This innovative platform not only enhances recruitment efforts, but also supports professional development and continuous quality improvement, ultimately leading to higher nurse satisfaction and retention. It’s a game-changer for operational excellence in healthcare.”

Nurse.com suggests positions that are the best fit for nurses based on skills and requirements tailored to each candidate. Nursing professionals highlight dissatisfaction with management (25%), better pay (24%), and more flexible hours (16%) as the main motivators for leaving their last position, according to Nurse.com’s 2024 Nurse Salary and Work-Life Report. Developed by nurses for nurses, this is the only intelligent career platform designed to truly understand its community’s unique needs, promoting optimal job pairing for both the candidate and the employer.

We offer a nurturing environment where nurses are encouraged to grow and thrive in their careers,” said Cara Lunsford, RN, VP of Community, Nurse.com, host of the NurseDot Podcast. “Our platform offers more than job listings; it’s a vibrant community where nurses find support, engage in lifelong learning, and build lasting connections with their peers. By providing access to industry-leading continuing education, engaging content, and a supportive community, Nurse.com ensures nurses will both visit our platform and stay, which is a significant advantage for recruiters looking to attract top talent.”

How Applied Research is Transforming Medical Device Startups | By Hannah Eherenfeldt, Co-founder & CEO of ReSuture

June 13, 2024

Medical device startups face numerous barriers when trying to penetrate the crowded startup landscape. Fundraising is highly competitive, and many products fail to reach the market due to insufficient funding for research, validation, and testing.

The applied research model provides a solution. This model leverages public-private partnerships to help startups accelerate their journey to commercialization. By following a specific formula, applied research supports startups in navigating the complexities of product development.

Our surgical training technology startup, ReSuture, has significantly benefited from the applied research model. My colleague, Ben Knapp, and I founded ReSuture in 2019 to offer surgeons a way to practice complex surgeries on models that accurately replicate human tissue.

As biomedical engineers, we have collaborated closely with medical device professionals to understand the industry’s needs. During our efforts to develop various training models for medical students and surgical residents, we identified a glaring need for improved hands-on training options.

Traditionally, surgical training occurs during live procedures in operating rooms. Our proprietary manufacturing technique allows us to produce realistic replicas of vascular structures, such as veins and arteries, incorporating disease-like conditions. This innovation offers a new method for creating synthetic vasculature, enabling surgeons to practice on the most life-like alternatives before performing on humans to test new devices or refine surgical techniques. Our technology is primarily utilized by medical device companies, which drive over 90% of ongoing surgical training.

For ReSuture, applied research has provided access to non-dilutive funding and a network of experts through partnerships with public and private sectors. Support from university researchers and local health systems has allowed our team to concentrate on testing and validating our technology, propelling us towards commercialization. Understanding and leveraging the applied research model can help both existing medical device companies and startups overcome entry barriers, accelerate commercialization, and drive innovation.

ReSuture and the Applied Research Model in Arizona

ReSuture is headquartered in Phoenix, AZ, and was inducted into the Partnership for Economic Innovation’s Arizona WearTech Center Applied Research Center as part of its third cohort in 2023. The WearTech Center has been instrumental in our early success, significantly expediting our development timeline.

Arizona’s biomedical, semiconductor, and technology industries have grown rapidly over the past decade. Industry leaders have established a robust foundation to help startups bring transformative ideas to market. Originally launched in New Orleans as Tulane University graduates, we recognized the financial opportunities in Arizona’s bioscience sector and vibrant research ecosystem, prompting our strategic relocation.

Support in research and development, prototyping, and validation has been pivotal to ReSuture’s success. Recently, we secured a patent for our novel manufacturing method, underscoring the uniqueness of our synthetic vascular tissue and bolstering our credibility. The applied research framework has fostered critical collaborations with leading university research teams and health systems while streamlining access to both private and public funding sources through strategic partnerships.

Public-Private Partnerships

Developing technology to address complex challenges necessitates substantial financial, technical, and strategic support. As a startup, ReSuture has had to cultivate this support from the ground up. We have navigated the competitive startup landscape with the aid of both public and private investments, leveraging state and national government funding streams to focus on bringing our products to market.

A pivotal factor in our success has been the support from local Arizona programs funded by the Arizona Commerce Authority, including the WearTech Center and Venture Ready Accelerator. These initiatives have provided invaluable assistance in refining our business plans, enhancing our go-to-market strategies, and increasing our investor pitch readiness.

The Arizona Commerce Authority has also connected us with a network of business and financial mentors, high-level executives, and subject-matter experts, further aiding our growth and fundraising efforts.

Additionally, ReSuture has received substantial support from the National Science Foundation (NSF) in the form of two Small Business Innovation Research (SBIR) awards, totaling over $1.2 million. Our most recent Phase II SBIR grant has enabled us to integrate cutting-edge sensing technologies into our models, allowing us to capture critical data on surgical tool movement and the forces applied during procedures. This advancement significantly furthers our mission to improve surgical training.

Leveraging Local Health Systems

Validation is one of the most significant hurdles in research and development. The applied research model offers a strategy to streamline and expedite this lengthy and cost-intensive process. Building relationships with industry experts can be the missing link to achieving validation, and for us, the applied research model has been instrumental in bridging complex and segmented systems.

ReSuture’s robust research partnerships with local health systems, including St. Joseph’s Hospital and Medical Center and the Mayo Clinic, have been crucial. These collaborations allow us to understand and address the challenges medical professionals encounter in their daily environments. Relying on these partnerships has also been essential in overcoming internal obstacles, such as the lack of infrastructure needed to bring our products to market.

As surgeons use our models to learn and practice new techniques, we collect data to establish objective and well-defined performance metrics for surgical procedures. This data is invaluable as we develop sensing technology and machine learning algorithms to measure and differentiate surgical skills effectively. Additionally, it provides critical insights into the performance of medical devices and surgeons during simulated operations, which can be applied to real surgeries.

Collaborating with University Researchers to Respond to Market Needs

ReSuture’s partnerships with researchers at Arizona State University’s School of Computing and Augmented Intelligence have been pivotal in advancing our data analytics capabilities, an experimental platform that aims to enhance both medical device performance and surgical skills.

Arizona State University, a globally recognized research institution, has been a critical partner in transforming our ideas into impactful solutions. Collaborating with ASU faculty and staff has provided us with access to a vast network of experts and state-of-the-art lab technology. This partnership has been especially beneficial in our efforts to develop the machine-learning algorithms that power our surgical data analytics platform.

This collaboration significantly boosts ReSuture’s credibility, making potential customers and stakeholders more inclined to trust and support our future growth initiatives. Partnering with a prestigious research institution not only strengthens our reputation but also aligns us with renowned experts and the latest advancements in medical research.

Conclusion

Arizona, as an emerging innovation hub, offers businesses and startups numerous opportunities to transform ideas into tangible solutions that enhance patient care.

With the support of the WearTech Center and a commitment to interdisciplinary partnerships, ReSuture is expanding its network both within Arizona and across the nation. We are currently experiencing a remarkable period of growth and development, highlighted by the recent acquisition of our first patent. We are proud of the significant progress we have made toward our ultimate goal: providing the medical device industry and surgeons with objective metrics for surgical performance.

Editor’s Note: Hannah Eherenfeldt, CEO and Co-Founder of ReSuture: Hannah Eherenfeldt leads ReSuture with a background in engineering and entrepreneurship. Before founding ReSuture, she worked with early-stage biotechnology startups as part of the commercialization team at the New Orleans Bioinnovation Center. With a strong affinity for design and product development, Hannah leverages her expertise to drive innovation and growth. She holds a Bachelor of Science in Engineering (BSE) in Biomedical Engineering from Tulane University.

Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility

June 13, 2024

Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, received a signed $30 million purchase order from Nephron Pharmaceuticals, representing their first 12 months of syringe purchase commitments. The purchase order includes deliveries for both the 10mL and 50mL specialty copolymer prefillable syringes that will be manufactured at the West Columbia site being acquired from Nephron. This assurance of supply is expected to support the planned expansion of the 503b operations at the Nephron site. The new copolymer syringe technology reflects the pharmaceutical and healthcare industry’s trend toward transitioning injectable drug therapies into innovative polymer prefillable syringes and away from the older glass and standard plastic syringes.

Braden Miller, Sharps Technology Director of Product Development, commented,

“Sharps has developed an exciting alternative to glass syringes through the use of molded inert polymers, offering a high-quality solution compared to traditional glass syringe systems.” Sharps prefillable polymer syringes have many of the same characteristics as traditional glass designs to support long term drug stability and increase shelf life for pharma and healthcare customers. However, polymer syringes can also be made into custom configurations with unique container closure systems; they can nearly eliminate breakage, minimize dead space, reduce contamination, excel in cold-chain storage, and support the development of novel devices including autoinjectors. The ability to produce these innovative syringe products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance, and safety when compared to similar glass syringe products.

Sharps Technology recently signed, and is working to close on, an enhanced Asset Purchase Agreement and accompanying five-year, $200 million Syringe Sales Agreement with Nephron. These agreements are expected to close before the end of July, although there can be no assurance. The purchase order is conditioned on the closing of the Asset Purchase Agreement. Once finalized and closed, Sharps will become the first fully dedicated, specialized polymer prefillable syringe manufacturing plant in North America. The state-of-the-art syringe facility will be on track to begin product deliveries in the second quarter of 2025, with projected revenue expected to exceed $35 million for the first 12 months of sales.

“Once the enhanced deal with Nephron was negotiated and signed, everything began moving at an accelerated pace. Sharps is so pleased that Nephron has been willing to issue this Purchase Order now. It speaks to the collaborative relationship between our companies and the long partnership we want to have with Nephron,” commented Robert Hayes, Sharps Technology CEO. “We really look forward to this exciting chapter for Sharps Technology. The PO from Nephron is tangible evidence that our hard work is showing results.”

With the $1 million escrow deposit in place, Sharps has been given access to the facility to begin key start-up activities and meetings with large US-based healthcare customers to support new sales opportunities for 2025. The Sharps team will continue to work behind the scenes, with contracted industry resources, to expedite its manufacturing implementation plan and get its product qualified for shipment to commercial customers as quickly as possible. As soon as the asset acquisition is closed, which is expected before the end of July, Sharps will immediately move forward with the first phase of its manufacturing implementation plan. This includes the final facility buildout and planned upgrades to support the manufacture of pharmaceutical-grade COC prefillable syringes on three state-of-the-art production lines. Product from the first production line will be qualified to ship in the second quarter of 2025, and all three lines are expected to ship product by the fourth quarter of 2025. A second and third phase will also be implemented and are expected to be completed by October 2027. Sharps’ revenue is expected to exceed $35 million during the first 12 months of sales. The South Carolina facility has sufficient additional capacity to generate revenue of more than $50 million in 2026 and has the capacity to grow to over $100 million in revenue by 2028 within the current facility.

What Are The Benefits of Regular Pediatric Check-Ups?

June 12, 2024

As a parent, ensuring your child’s health and well-being is crucial. One effective way to protect your child’s health is by scheduling checkups with professionals with formal qualifications like online family nurse practitioner programs, among others. These appointments are not about treating illnesses but monitoring and supporting your child’s growth and health. This article will discuss the advantages of pediatric checkups for both children and parents, emphasizing their role in promoting lifelong wellness.

When Should I Schedule Check-ups for My Child?

The frequency of check-ups varies depending on your child’s age. Knowing these schedules can help parents manage their child’s healthcare effectively. While it’s okay to increase visits, if you have concerns, let’s review some schedules for child check-ups.

Infants are recommended to have a check-up during the week after birth, followed by visits at 1, 2, 4, 6, 7, and 12 months. This schedule is advised because the early stages of life are often the most critical. During the three years of a child’s life, the visit schedule changes, with appointments set at 15, 18, 24, and 30 months. After this phase, kids should have checkups until they reach their teenage years.

Advantages of Regular Pediatric Check-ups for Children’s Health

Regular visits offer numerous health benefits for children. It’s crucial not to overlook the years but to recognize the advantages of consistent check-ups later. Here are some key benefits to consider for your child.

Early Detection of Health Complications

One of the perks of regular checkups is the early identification of potential health issues. This aspect is essential as it allows healthcare professionals to detect and address various problems. These include delays that could affect a child’s growth, concerns that might impact their social interactions, and chronic conditions that could influence their overall well-being.

Detecting issues early enables intervention through treatments and strategies. Taking this approach ensures health outcomes, offers parents peace of mind, and equips them with essential guidance to support their child’s health and development effectively.

Administration of Immunizations

Vaccinations are crucial in children’s healthcare, acting as a barrier against severe diseases that could be life-threatening. By staying on top of check-ups, parents can ensure their child gets all the immunizations at the correct times according to the recommended schedule based on age.

This approach protects each child’s health and helps prevent widespread outbreaks of contagious diseases in communities. Providing timely vaccinations is an aspect of creating a disease-free environment in which our children can thrive.

Growth and Development Tracking

Tracking a child’s growth and development is an integral part of parenting and pediatric care and is usually done during visits. These measurements ensure that your child grows correctly and at the expected pace while examining other developments like language and motor skills.

Monitoring these milestones gives parents peace of mind about their child’s health and progress. It also enables detection and assistance if any developmental delays or concerns are detected, guaranteeing that the child gets support promptly.

Expert Advice

With their expertise in children’s health, pediatricians offer guidance on a wide range of topics crucial for child development. This includes expert nutrition advice to ensure children receive the nutrients they need for growth and recommendations on establishing healthy sleep routines, which are vital for a child’s physical and cognitive progress.

Furthermore, pediatricians provide tips for managing childhood illnesses, from the flu to persistent conditions, empowering parents with the information needed to make informed choices. Through this assistance, pediatricians play a role in fostering a child’s health and well-being, ensuring they have a solid foundation for a healthy life.

The Importance of Regular Checkups-up and the Relationship Between Doctor and Parent

Establishing a trusting bond with your child’s pediatrician is advantageous and priceless because regular checkups go beyond appointments. They encourage communication between parents and healthcare professionals, which is essential for the child’s well-being. These regular visits with your child’s doctor help coordinate care in the long term to understand your child’s health history.

It also ensures that the pediatrician knows your child’s needs, preferences, and potential worries well, allowing for care that can significantly impact your child’s health in a positive way. Ensure that you start developing good relationships early so that your child will have the highest chance of success because the pediatrician knows their history.

Conclusion

Regular checkups with a pediatrician are vital for healthcare, offering advantages for both kids and parents. By prioritizing these appointments, you invest in your child’s long-term well-being by detecting issues, staying current on immunizations, and building a relationship with the pediatrician. Make regular pediatric visits a priority in your family routine to promote health commitment, and you never know, it might just save your child from debilitating conditions or complications down the road.

Flow Cytometry Market Surges to $10.3 Billion by 2032, Driven by 9.2% CAGR Growth

June 11, 2024

The global flow cytometry market, valued at $5.1 billion in 2024, is primed for substantial growth, projected to achieve a remarkable compound annual growth rate (CAGR) of 9.2% over the forecast period, ultimately reaching $10.3 billion by 2032. This expansive market ecosystem encompasses an array of activities spanning the production, distribution, and utilization of flow cytometry instruments, reagents, and associated services, with industry behemoths such as Becton, Dickinson and Company, Danaher Corporation, and Thermo Fisher Scientific Inc. at the forefront. Driving this growth are relentless technological innovations, escalating adoption rates in clinical diagnostics, and the seamless integration of artificial intelligence and machine learning, all culminating in augmented data analysis capabilities. Yet, persistent challenges persist, notably the substantial capital outlay required for instrument acquisition and upkeep, alongside the intricate nature of reagent development. Nevertheless, avenues of opportunity abound, particularly within burgeoning clinical applications, propelled by ongoing advancements in instrumentation and automation. Presently, North America commands a dominant market share, with the Asia Pacific region poised for significant growth, underpinned by burgeoning healthcare expenditures and supportive governmental initiatives fostering market expansion.

Browse in-depth TOC on “Flow Cytometry Market“

713 – Tables
56 – Figures
559 – Pages

Innovative Advancements Propel Growth

In the dynamic global flow cytometry market, the introduction of cutting-edge technological advancements propels market expansion by catering to the demand for enhanced workflow efficiency and superior performance. Key players are continually innovating to develop and commercialize advanced flow cytometry products with features such as multiplexing capabilities, higher throughput systems, and improved data analysis software. These innovations not only bolster the efficiency, sensitivity, and accuracy of flow cytometry assays but also make them more appealing for both research and clinical applications. For instance, the BD FACSDiscover S8 Cell Sorter, introduced by Becton, Dickinson and Company in April 2024, exemplifies the integration of real-time imaging and spectral flow cytometry capabilities, catering to evolving market needs.

Cost Barrier Challenges Market Adoption

However, the high cost associated with flow cytometry instruments poses a significant challenge to market growth. Clinical laboratories, research facilities, and pharmaceutical companies often require multiple instruments for concurrent research studies, leading to substantial capital investment and maintenance costs. Limited budgets, especially in academic and research laboratories, further exacerbate this issue, hindering widespread adoption, particularly among smaller institutions with constrained financial resources. Additionally, the elevated product installation costs and associated overheads present significant barriers to implementation, particularly in emerging markets where healthcare infrastructure may be underdeveloped.

Clinical Applications Present Lucrative Opportunities

Despite these challenges, the expanding utilization of flow cytometry in clinical applications and infectious disease diagnostics presents lucrative growth opportunities for market players. Flow cytometry’s ability to analyze cellular characteristics and biomarkers has revolutionized disease diagnosis, prognosis, and monitoring in various fields, including hematology and immunology. For example, flow cytometry plays a crucial role in diagnosing and monitoring hematological malignancies, such as leukemia and lymphoma, by analyzing cell surface marker expression patterns. Moreover, advancements in instrumentation, automation, and assay development, coupled with regulatory clearances like the DxFLEX Clinical Flow Cytometer from Beckman Coulter, underscore flow cytometry’s importance in precision medicine and its potential to drive further market expansion.

Reagent Development Complexity

Nevertheless, complexities related to reagent development remain a significant challenge in the flow cytometry market. Developing high-quality reagents with optimal specificity, sensitivity, and stability is a time-consuming and resource-intensive process, requiring extensive testing and validation to ensure reproducible results across diverse applications and laboratory settings. Despite these challenges, ongoing advancements in reagent development hold promise for unlocking the full potential of flow cytometry in various research and clinical applications, underscoring the resilience and adaptability of the market in overcoming obstacles and driving continued innovation.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584

Reagents & Consumables Dominate Market

The reagents & consumables segment dominated the flow cytometry industry in 2023, fueled by advancements in reagents, increased research & development activities, and the adoption of flow cytometry in clinical applications. This segment, further subdivided into antibodies, assays & kits, and other reagents & consumables, holds sway due to its crucial role in facilitating accurate analysis and experimentation in flow cytometry processes.

Academic & Research Institutes Poised for Growth

Academic & research institutes are projected to experience substantial growth at a significant CAGR throughout the flow cytometry industry forecast period. This growth is driven by increased investment in clinical trials, drug development, and biopharmaceutical research, alongside rising demand for advanced technologies and high-throughput capabilities. Significant funding and grants for scientific research further bolster this segment’s expansion.

North America Leads Industry in 2023

North America emerged as the dominant force in the global flow cytometry industry in 2023, surpassing other regions such as Europe, Asia Pacific, Latin America, the Middle East, and Africa. Its leadership position is attributed to robust healthcare infrastructure, substantial investment in research and development, and high adoption rates of advanced technologies. The presence of leading market players, extensive clinical research activities, and favorable regulatory policies reinforce North America’s stronghold in the flow cytometry market.

Asia Pacific’s Growth Trajectory

The Asia Pacific region is poised to witness significant growth during the forecast period of 2024-2032. Factors driving this growth include the increasing prevalence of chronic diseases, rising healthcare expenditure, and supportive government initiatives promoting the adoption of flow cytometry technologies across various applications. This burgeoning market expansion in the Asia Pacific region underscores its potential to emerge as a key player in the global flow cytometry landscape.

Key Players Driving Innovation

Leading the charge in the flow cytometry market are key players such as Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), Sony Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux (France), Cytonome/ST, LLC (US), Sartorius AG (Germany), and Cytek Biosciences (US), among others. These industry giants continually drive innovation and shape the market landscape through their cutting-edge technologies and solutions.

Recent Technological Advancements

Recent developments in the flow cytometry industry highlight the relentless pursuit of innovation among market players. In May 2024, Agilent Technologies Inc. unveiled the NovoCyte Opteon Spectral Flow Cytometer, offering configurations ranging from three to five lasers and supporting up to 73 high-quality detectors. Beckman Coulter introduced the CytoFLEX nano Flow Cytometer in March 2024, featuring simultaneous multiparameter detection powered by six fluorescent detection channels and five side scatter channels. Sony Corporation launched the FP7000 spectral cell sorter in October 2023, supporting high-speed, high-parameter sorting with more than 44 colors and leveraging patented spectral technology-based optics, advanced electronics, and fluidics. Additionally, in March 2023, BD (Becton, Dickinson and Company) launched the BD FACSDiscover S8 Cell Sorter, the world’s first spectral cell sorter with high-speed cell imaging, further exemplifying the industry’s commitment to pushing technological boundaries and driving innovation forward.

Archer Review Unveils Cutting-Edge Products Catering to Every Stage of the Nurse Life Cycle

June 11, 2024

Archer Review, renowned for its affordable and high-quality NCLEX board preparation services, is thrilled to announce the launch of three new products designed to support nurses throughout their careers. The new offerings include the TEAS 7 pre-nursing exam preparation, Family Nurse Practitioner (FNP) and Adult-Gerontology Nurse Practitioner (AGNP) board preparation, and a comprehensive Nursing School companion product aimed at enhancing learning during the entire nursing education journey.

Archer Review’s TEAS 7 pre-nursing exam preparation course is meticulously crafted to help aspiring nursing students excel in their admission tests. The course provides extensive coverage of all TEAS 7 test sections, including Reading, Mathematics, Science, and English & Language Usage. It features over 1,500 interactive practice questions with detailed rationales, full-length practice exams simulating the actual test environment, and beautifully detailed video learning modules that keep students on track. Personalized tutoring services are also available to target weaknesses, ensuring each student can maximize their potential.

“Our mission at Archer Review has always been to empower nursing students with the best tools and resources to succeed,” said Morgan Taylor, DNP, CPNP-PC, CNO of Archer Review. “With the launch of these new products, we are extending our support to cover every stage of the nurse life cycle, from aspiring students to practicing professionals.”

Recognizing the needs of advanced practice nurses, Archer Review introduces a comprehensive preparation course for the Family Nurse Practitioner (FNP) and Adult- Gerontology Nurse Practitioner (AGNP) exams offered by both the American Nurses Credentialing Center (ANCC) and the American Association of Nurse Practitioners (AANP). This course includes extensive and engaging on-demand content review and a 1,500+ question bank for readiness exams, all within an interface that mirrors both exam formats. Archer Review has also launched an intensive 3-day live review that prepares students for the exam as well as tutoring and mentoring sessions with experienced FNPs to further set up students for success. To help students learn more about these services and experience the quality instruction firsthand before purchase, Archer Review is hosting two to three free live webinars every week on rotating clinical topics.

“Nursing is a journey that requires continuous learning and adaptation,” noted Rachel Ward, MSN, APRN FNP-BC, Director of Nurse Practitioner Programming at Archer Review. “We are excited to provide resources that not only prepare students for their exams but also support them throughout their entire career. When a new NP makes the shift from taking orders to writing prescriptions, it can feel a bit scary. We help the basics become second nature and engrain confidence in their own clinical decision making.”

Lastly, launching in September, Archer Review’s comprehensive nursing school companion product is designed to support students throughout their entire nursing education, enhancing learning and retention. It has 20 courses that cover all major nursing subjects taught during nursing school. The product features interactive case studies and clinical scenarios taught in over 850 videos to bridge theory with practice, includes more than 350 cheat sheets, and has a personalized dashboard reporting for quick identification of knowledge gaps. Students can purchase this product directly and nursing programs will also be able to purchase this program for their students. This helps nursing programs track baseline knowledge, enhance remediation tactics, and provide peer and faculty support for collaborative learning and mentorship.

Archer Review is proud to build on its success in the NCLEX board preparation space with these new products and continue to deliver best-in-class education at an affordable price. With a commitment to excellence and innovation, Archer Review continues to be a trusted partner in nursing education.

Powered By MRP Raises Series A Funding from Aries Capital Partners and Swell Collective

June 10, 2024

Globally recognized aesthetics device company Powered By MRP is pleased to announce a strategic partnership with prominent Utah-based Growth Equity firms, Aries Capital Partners and Swell Collective. The Series A investment marks a pivotal moment in Powered By MRP’s growth trajectory as it brings together unparalleled expertise and resources to accelerate the company’s expansion plans and market presence.

The round was led by Aries Capital Partners and Swell Collective.

Aries Capital Partners brings decades of experience in identifying and nurturing high-growth companies, the firm is led by Rick Durham and Jason Reading. Their commitment to fostering innovation and driving operational excellence aligns seamlessly with Powered By MRP’s mission to revolutionize the aesthetics device industry.

“The aesthetic device market has undergone dramatic transformation in the last five years and will continue to evolve quickly in how these devices are marketed and serviced,” said Jason Reading, Partner at Aries Capital Partners. “To meet this challenge, Scott Carson, Founder and CEO, has assembled a world-class team and a vision on how to better service the needs of both end-users and manufacturers of aesthetic laser devices. He has the clinician and business owner in mind and wants to make the process of buying, selling, and servicing devices transparent to the end-user. We are excited to partner with Scott and his team to make his vision a reality,” said Reading.
Swell Collective is a new growth equity fund led by experienced investors Aaron DeRose and Alex Daines, with Jeremy Andrus (current CEO of Traeger Grills and former CEO of Skullcandy) serving as an advisor and investor. The Swell Collective team has extensive experience investing in high-growth companies and understands deeply the nexus of consumer experience and technology. Their strong track record and operating background makes them an ideal partner for the next stage of growth for Powered By MRP.
“We became interested in MRP when we learned of the strong tailwinds behind the aesthetics market. When we met Scott and the rest of the Powered By MRP team, we quickly realized the amazing potential of the business,” said Alex Daines, Principal at Swell Collective. “With strong foundations already in place, this growth capital will help fuel Powered By MRP to be a dominant player in the aesthetics industry, while continuing to provide best-in-class service to the physicians and clinicians it serves.”
Since its founding in 2015, Powered By MRP has earned global recognition for its technology-driven platform. The company offers a vertically-integrated e-commerce platform that empowers aesthetic providers with consultative customer service and GPO-level pricing. As the largest reseller of new and pre-owned energy-based aesthetic and surgical devices worldwide, Powered By MRP continues to redefine industry standards and elevate customer experiences.

“As a data rich aesthetics device company, this partnership is a testament to our innovation and dedication to excellence,” said Scott Carson, Founder and CEO of Powered By MRP. “Now, being partially owned by two of the most prestigious Growth Equity firms in the country, we’re poised for even greater care to the physicians, clinicians and administrators we serve. I am proud of the entire MRP team that even in this very difficult equity market, MRP raised capital well above the median for a Series A, affirming our position as a leader in the industry and setting a new standard for growth and innovation,” he said.
As part of the transaction, Jason Reading (Aries) and Alex Daines (Swell) will be joining the Powered By MRP Board of Directors. This is alongside founding members Scott and Marilyn Carson as well as Jonathan Nielsen (previously Backcountry.com CEO). As the company enters its next stage of growth, deepening its e-commerce, technology infrastructure, and logistics platforms, both Jonathan Nielsen and Powered By MRP CFO Shaun Groat, will play integral roles in the company’s growth.
In alignment with its expansion strategy, Powered By MRP is actively planning to expand its facilities in key locations, including Salt Lake City and the Mid-Atlantic region. These expansion efforts signify the company’s commitment to meeting the growing demands of its customer base while solidifying its position as a leader in the market. “The capital raised enables us to expand our capabilities to better serve our customers and drive innovation and ultimately the cost of healthcare to all patients,” Carson concluded.

Other co-Investors in the Series A included Broadhaven Capital Partners, Jeff Lee and Chris Koh.

Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes

June 10, 2024

The U.S. Department of Justice (DOJ) and the U.S. Food and Drug Administration (FDA) today announced the creation of a federal multi-agency task force to combat the illegal distribution and sale of e-cigarettes.

Along with the FDA and the Justice Department, the task force will bring together multiple law enforcement partners, including the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF); the U.S. Marshals Service (USMS); the U.S. Postal Inspection Service (USPIS); and the Federal Trade Commission (FTC), to coordinate and streamline efforts to bring all available criminal and civil tools to bear against the illegal distribution and sale of e-cigarettes responsible for nicotine addiction among American youth. Additional agencies may join the task force in the coming weeks and months.

“Unauthorized e-cigarettes and vaping products continue to jeopardize the health of Americans – particularly children and adolescents – across the country,” said Acting Associate Attorney General Benjamin C. Mizer. “This interagency Task Force is dedicated to protecting Americans by combatting the unlawful sale and distribution of these products. And the establishment of this Task Force makes clear that vigorous enforcement of the tobacco laws is a government-wide priority.”

“The Justice Department is committed to enforcing the laws that prevent the sale and distribution of unlawful e-cigarettes,” said Principal Deputy Assistant Attorney General Brian Boynton, head of DOJ’s Civil Division. “We will work closely with our Task Force partners to address this crisis with all of the enforcement tools available to us.”

“Curbing the widespread availability of illegal ENDS products is a top priority of the Justice Department’s consumer protection efforts,” said Deputy Assistant Attorney General Arun G. Rao of the Civil Division’s Consumer Protection Branch. “Together with our law enforcement partners, we look forward to advancing aggressive and innovative solutions to the unique and constantly evolving problem of illegal vaping products.”

“Enforcement against illegal e-cigarettes is a multi-pronged issue that necessitates a multi-pronged response,” said Dr. Brian King, director of the FDA’s Center for Tobacco Products. “This ‘All Government’ approach – including the creation of this new Task Force – will bring the collective resources and experience of the federal government to bear on this pressing public health issue.”

The 2023 National Youth Tobacco Survey found that about 2.1 million youths reported currently using e-cigarettes, which reflects a considerable decline from 5.3 million youth in 2019. However, 10 percent of high school students and almost five percent of middle school students reported currently using e-cigarettes, and more than one in four of those e-cigarette users reported daily e-cigarette use. Manufacturers, distributors and retailers market a wide range of products that appeal directly to school-age users, such as candy and fruit flavors, some of which come in devices designed to be easily concealed.

Youth use of tobacco products in any form – including e-cigarettes – is unsafe. According to the CDC, nicotine poses unique dangers to young people. In addition to being highly addictive, nicotine can harm the developing adolescent brain, which continues to develop until about age 25. Young people who use nicotine may also be at risk for addiction to other drugs.

To date, the FDA has authorized the sale of 23 specific tobacco-flavored e-cigarette products and devices. These are the only e-cigarette products that currently may be lawfully marketed and sold in the United States. To date, the FDA has issued more than 1,100 warning letters to manufacturers, importers, distributors and retailers for illegally selling and/or distributing unauthorized new tobacco products, including e-cigarettes, and has filed civil money penalty complaints against more than 55 manufacturers and 140 retailers for the manufacture and/or sale of unauthorized tobacco products. In addition, the FDA and the Justice Department have obtained injunctions against six manufacturers to stop them from manufacturing and selling unauthorized e-cigarette products.

The federal task force will focus on several topics, including investigating and prosecuting new criminal, civil, seizure and forfeiture actions under the PACT Act; the Federal Food, Drug, and Cosmetic Act (FDCA), as amended by the Family Smoking Prevention and Tobacco Control Act (TCA); and other authorities. Violations of these statutes can result in felony convictions and significant criminal fines and civil monetary penalties. They can also result in seizures of unauthorized products, which can help to make illegal e-cigarettes less accessible, including to young people. Through their participation in the task force, USMS will help the FDA and the Department effectuate seizures of unauthorized e-cigarettes within the United States.

“The U.S. Marshals Service Asset Forfeiture Division stands ready to work with our Task Force partners in the seizure of unauthorized e-cigarettes from domestic distributors seeking to sell them unlawfully,” said Ronald L. Davis, director of the U.S. Marshals Service.

The Justice Department is also collaborating with ATF and USPIS on potential criminal and civil enforcement actions under the Prevent All Cigarette Trafficking Act of 2009 (PACT Act). The PACT Act requires online sellers of ENDS products to register with ATF and to verify the age of purchasers both at the point of sale and the point of delivery, as well as to comply with tax collection provisions and state and local laws. The task force announced today will support these actions and coordinate enforcement strategies the FDA and the Justice Department are working on with multiple agency partners.

“The PACT Act is an important tool for preventing the unlawful sale of e-cigarettes to minors online. ATF looks forward to working with other components of the Department of Justice and USPIS to enforce the law,” said ATF Director Steven M. Dettelbach.

“The U.S. Postal Inspection Service is committed to working with the Task Force to investigate violations of the PACT Act and other statutes that govern the distribution of e-cigarettes through the mails,” said Chief Postal Inspector Gary R. Barksdale.

Finally, the Federal Trade Commission (FTC), which releases reports about cigarette, smokeless tobacco and e-cigarette marketing, and enforces various statutory and regulatory prohibitions on false and misleading advertising, will support the activities of the task force, including by sharing its knowledge about the marketplace for vaping products.

“We look forward to sharing our experience with this rapidly changing, multi-billion dollar market through this important Task Force,” said Samuel A.A. Levine, director of the FTC’s Bureau of Consumer Protection.

For more information on e-cigarette regulation, including legal compliance and enforcement efforts, see the FDA’s website at https://www.fda.gov/tobacco-products and the ATF’s website at https://www.atf.gov/alcohol-tobacco/vapes-and-e-cigarettes.

Key findings from the survey include:

When Should I Schedule Check-ups for My Child?

Advantages of Regular Pediatric Check-ups for Children’s Health

Early Detection of Health Complications

Administration of Immunizations

Growth and Development Tracking

Expert Advice

The Importance of Regular Checkups-up and the Relationship Between Doctor and Parent

Conclusion

Medical Device News Magazine